Tao (Tony) Zhang Hits Amazon Best-Seller Status with ‘Strategic Conversations' Book Co-Authored with Chris Voss
APEX, NC, UNITED STATES, March 16, 2025 / EINPresswire.com / -- SuccessBooks® proudly celebrates the outstanding achievement of 'Strategic Conversations' co-authored by Tony Zhang, alongside Chris Voss and distinguished professionals worldwide. Launched on March 6th, 2025, the book has achieved Amazon Best-Seller status, marking a significant milestone in its journey.
Strategic Conversations has achieved outstanding success, ranking on multiple Amazon Best Seller lists and maintaining strong momentum in the New Release categories. Its impressive placements in Direct Marketing, Marketing, Communication Skills, and Entrepreneurship reflect its impact and relevance in today's business landscape. This achievement highlights the book's value in helping professionals elevate their strategic communication and business growth.
Central to the success of 'Strategic Conversations' is Tony Zhang's chapter, 'Learn Differently.' Tony shares a powerful journey of personal and professional transformation, realizing the importance of continuous growth, curiosity, and self-awareness, he embraces a new mindset, becoming an advocate for lifelong learning.
Meet Tao (Tony) Zhang:
Tao Zhang's journey is a testament to resilience and transformation. Born in a small city in central China, Tao grew up in a close-knit family and came to understand the sacrifices his parents made to secure his happiness and opportunities. Driven by a deep sense of gratitude, he embraced the challenge of pursuing a higher education path—despite being the lowest-ranked student in his class. His determination ultimately led him to the top high school in the region, and this persistence became the foundation of his future success.
His approach to life has always been marked by passion, whether in academics, sports, or even digital gaming. Tao's knack for strategic thinking translated seamlessly into professional success, enabling him to achieve prestigious IT certifications and lead large-scale projects across Asia. One pivotal project—a significant SAP implementation—brought him to the United States, where he quickly became the youngest partner in his mentor's firm.
By the early 2010s, Tao had reached impressive career milestones, achieving financial success beyond his expectations. Yet, he faced an existential realization: he had reached his career peak in his 30s. This insight propelled him toward new challenges and inspired him to invest in startups—ventures distinct from the Fortune 500 clients he had served. Although his entrepreneurial journey included financial setbacks, it sparked a profound question: Were his ventures truly learning from their experiences?
This question fueled Tao's immersion in the science backed platform economy, a field he has actively contributed to since 2014. Through his work with Apex Learn, he has dedicated himself to helping adults develop First Principle Thinking, using platform-based environments to promote psychology, neuroscience and innovation theories and foster meaningful and lasting change. Tao's commitment to lifelong learning and innovation aligns with his mission to empower others on their journeys of self-discovery and growth.
SuccessBooks®
email us here
Legal Disclaimer:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
High Growth Tech Stocks To Watch In Europe June 2025
As the European markets experience a boost, with the STOXX Europe 600 Index climbing by 0.90% amid easing inflation and supportive monetary policy from the European Central Bank, investors are increasingly focusing on high-growth sectors such as technology. In this environment, identifying promising tech stocks involves looking for companies that can leverage favorable economic conditions and technological advancements to drive substantial growth. Name Revenue Growth Earnings Growth Growth Rating Intellego Technologies 30.80% 45.66% ★★★★★★ Archos 21.07% 36.58% ★★★★★★ KebNi 21.51% 66.96% ★★★★★★ Pharma Mar 29.61% 44.92% ★★★★★★ Bonesupport Holding 29.14% 56.14% ★★★★★★ argenx 21.50% 26.61% ★★★★★★ Skolon 31.51% 99.52% ★★★★★★ Xbrane Biopharma 24.95% 56.77% ★★★★★★ Diamyd Medical 86.29% 93.04% ★★★★★★ Elliptic Laboratories 36.33% 78.99% ★★★★★★ Click here to see the full list of 226 stocks from our European High Growth Tech and AI Stocks screener. Let's explore several standout options from the results in the screener. Simply Wall St Growth Rating: ★★★★★★ Overview: argenx SE is a commercial-stage biopharma company focused on developing therapies for autoimmune diseases across several countries including the United States, Japan, China, and the Netherlands, with a market cap of €31.52 billion. Operations: argenx focuses on developing therapies for autoimmune diseases, generating revenue primarily from its biotechnology segment, which reported $2.64 billion. The company's operations span multiple countries, including the United States, Japan, China, and the Netherlands. argenx SE has demonstrated remarkable growth with a surge in revenue to $807.37 million, doubling from the previous year's $412.51 million, alongside transitioning from a net loss to a substantial net income of $169.47 million. This financial turnaround is underscored by robust R&D commitments, crucial for sustaining innovation and competitiveness in the biotech landscape. The firm's recent CHMP nod for VYVGART® in CIDP treatment further highlights its strategic focus on expanding therapeutic applications, promising continued relevance and impact within the healthcare sector. Click here to discover the nuances of argenx with our detailed analytical health report. Understand argenx's track record by examining our Past report. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Believe S.A. is a company that offers digital music services to independent labels and local artists across various regions including France, Germany, the rest of Europe, the Americas, Asia, Oceania, and the Pacific with a market cap of approximately €1.72 billion. Operations: The company's revenue primarily comes from Premium Solutions, generating €924.24 million, while Automated Solutions contribute €64.59 million. Believe, a European tech entity, is navigating its path towards profitability with expected earnings growth of 96.9% annually. Despite current unprofitability, its revenue growth outpaces the French market's average at 13.4% per year compared to 5%. This growth trajectory is supported by strategic moves such as the proposed acquisition by TCMI Inc., EQT X, and Denis Ladegaillerie for a €57.9 million stake, enhancing financial stability and market presence. Moreover, Believe's commitment to R&D aligns with industry demands for continuous innovation, ensuring it remains competitive in the dynamic tech landscape. Get an in-depth perspective on Believe's performance by reading our health report here. Examine Believe's past performance report to understand how it has performed in the past. Simply Wall St Growth Rating: ★★★★★☆ Overview: Comet Holding AG, along with its subsidiaries, delivers X-ray and radio frequency (RF) power technology solutions globally across Europe, North America, and Asia, with a market capitalization of CHF1.79 billion. Operations: The company generates revenue through three main segments: X-Ray Systems (CHF115.89 million), Industrial X-Ray Modules (CHF94.57 million), and Plasma Control Technologies (CHF247.39 million). Comet Holding AG, a Swiss tech firm, is making notable strides with an earnings growth of 37.3% annually, significantly outpacing the local market's average of 10.7%. This robust performance is further underscored by its revenue increase of 12.2% per year, which also surpasses the Swiss market growth rate of 4.2%. Notably, Comet's commitment to innovation is evident in its R&D spending, crucial for maintaining technological leadership in a competitive sector. Recent corporate actions include electing Benjamin Loh as Chairman and approving a dividend increase to CHF 1.50 per share, signaling strong governance and shareholder confidence amidst a promising financial trajectory marked by first-quarter sales surging by 37.5% year-over-year to CHF 111.2 million. Take a closer look at Comet Holding's potential here in our health report. Assess Comet Holding's past performance with our detailed historical performance reports. Dive into all 226 of the European High Growth Tech and AI Stocks we have identified here. Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments. Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ENXTBR:ARGX ENXTPA:BLV and SWX:COTN. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
3 hours ago
- Yahoo
Amazon and US rivals navigate volatile tariff landscape
The upcoming Amazon Prime Day 2025 arrives the United States amid widespread concern over shifting US-China trade policies, with tariff uncertainty casting a shadow over pricing, supply chains and sales strategies. Despite a temporary reduction in tariffs on Chinese imports, many e-commerce sellers and retail giants such as Amazon, Walmart and Target remain cautious ahead of one of the year's biggest online shopping events. Retail executives have repeatedly flagged the volatile tariff landscape as a top risk for their operations. Amazon's CFO Brian Olsavsky said the company's latest forecast reflects 'the general uncertainty' in global trade. His comments echoed warnings from Walmart and Best Buy leaders, who cited unpredictability around tariff levels and timing as a challenge for strategic planning. The U.S.-China tariff standoff had reached a peak earlier this year when import duties on Chinese goods soared to 145%. That prompted some brands to consider scaling back participation in Prime Day. A late-May agreement reduced those tariffs to 30%, offering temporary relief. Still, concerns remain as the legal status of tariffs continues to fluctuate, with pending court rulings expected to shape the near-term trade environment. Pattern, a commerce accelerator that works with brands across online marketplaces, reported scrambling to restock U.S. inventories after the tariff rollback. 'We were on the precipice,' said Brett Bardsley, the company's Chief International Officer, describing how airfreight and expedited shipping were used to fill gaps caused by earlier trade disruptions. For many sellers, Prime Day remains a high-stakes opportunity. More than 80% of Amazon Prime members surveyed in May indicated they plan to shop during the event—up from 68% in 2024—according to Tinuiti. Amazon is expected to stretch the sale across four days, doubling last year's duration. Still, not all brands are equally positioned. Companies heavily reliant on Chinese manufacturing are weighing whether they can offer competitive discounts while absorbing a 30% tariff. Others, like Flaus, a maker of electric flossers, say the lowered tariffs cleared the way for full Prime Day participation without raising prices—for now. Amazon has said it is pleased with the response from selling partners and is working to help them adapt. But categories like electronics, which have tighter margins and higher exposure to Chinese sourcing, may proceed cautiously. Shares in Amazon rebounded sharply in May after the tariff deal, gaining 11% for the month. That followed months of volatility tied to trade developments and investor concerns about rising costs and consumer demand. The stock remains just below a key technical buy point as of early June. While Amazon's e-commerce platform has not seen a significant rise in average selling prices, other retailers are less optimistic. Walmart's CFO John David Rainey recently warned that tariffs remain 'too high,' suggesting that shoppers could see price increases in the months ahead. The Trump administration, however, has pushed back against such claims, arguing that the current tariff policy is manageable for most businesses. Amazon's CEO Andy Jassy maintains that the company is well-positioned to gain market share during uncertain periods, citing its performance during past disruptions. Analysts say that while summer sales could see a lift from the tariff reprieve, the broader retail sector must still contend with unresolved trade tensions, inflationary pressure and shifting consumer sentiment. As the Supreme Court prepares to weigh in on the legality of current tariffs, industry watchers say retail strategies for the rest of 2025 will likely hinge on how trade policies evolve—and whether businesses can continue to absorb new costs without passing them on to consumers. Navigate the shifting tariff landscape with real-time data and market-leading analysis. Request a free demo for GlobalData's Strategic Intelligence . "Amazon and US rivals navigate volatile tariff landscape" was originally created and published by Retail Insight Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
3 hours ago
- Business Upturn
Glenmark Pharmaceuticals to launch Zanubrutinib (BRUKINSA) in India after DCGI approval
Glenmark Pharmaceuticals has announced the launch of zanubrutinib in India following approval by the Drugs Controller General of India (DCGI). The drug will be marketed under the brand name BRUKINSA®, developed by BeiGene (now BeOne Medicines), a global oncology company. This marks the introduction of the first Bruton's tyrosine kinase (BTK) inhibitor in India approved for the treatment of five B-cell malignancies: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and follicular lymphoma (FL). BRUKINSA is approved in over 70 countries, backed by data from clinical studies such as ALPINE, ASPEN, and SEQUOIA. These trials have demonstrated consistent clinical outcomes across various B-cell cancers. The availability of BRUKINSA in India comes at a time when blood cancers continue to impact a large number of individuals. Estimates suggest that someone is diagnosed with blood cancer every five minutes in India, with annual deaths from the disease numbering around 70,000. The treatment has shown high response rates and the ability to maintain disease control in patients with different types of B-cell malignancies. It also offers dosing flexibility, allowing for once or twice-daily administration. In the ALPINE study, BRUKINSA was compared with ibrutinib in relapsed or refractory CLL and showed a lower rate of serious cardiac events and fewer treatment discontinuations due to cardiac-related issues. With its recent regulatory approval, BRUKINSA will now be available to patients in India who are affected by challenging hematological cancers. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
